Latest on Pharmaceutical Industry

news

Celgene abandons Crohn's drug trials, shares drop

Celgene Corp said it would abandon testing a drug to treat Crohn’s disease, in a major setback to the U.S. biotechnology company’s pipeline amid attempts to lower dependence on its mainstay Revilimid. The company..Read More...

Novartis to shut U.S. generics plant, cut 450 jobs

Swiss drugmaker Novartis is to cut 450 jobs in the United States over the next two years as it gradually shuts a generics manufacturing plant in Colorado and discontinues some products in the face of intense price pressu..Read More...

events

24

3rd Annual Next Generation Sequencing USA Congress

Hyatt Regency Boston,
USA,
Oxford Global Marketing Ltd

24

3rd Annual Single Cell Analysis USA Congress

Hyatt Regency Boston,
USA,
Oxford Global Marketing Ltd

Press Releases

Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis®

Imprimis Pharmaceuticals Inc an ophthalmologyfocused pharmaceutical company today announced it is making compounded Cyclosporinebased formulations available for physicians to consider prescribing as customizable and pote.. Read More...

Concert Pharmaceuticals Announces PTAB Denies Incyte Petition Challenging CTP-543 Patent

Concert Pharmaceuticals Inc announced that the Patent Trials and Appeal Board PTAB of the US Patent and Trademark Office has denied Incytes petition to institute inter partes review IPR of US Patent No 9249149 the 149 pa.. Read More...

Suppliers of the Month

Product Launch

Articles

Videos

Latest Reports

whitepapers

Latest Projects

testimonials

Expert Talk

Bayer Pharmaceuticals

Bayer Pharmaceuticals Christoph Huwe PhD CAAM is a Strategic Alliance Manager Therapeutics at Bayer AG Pharmaceuticals with a focus on the BayerEvotec Endometriosis BayerEvotec Kidney Diseases BayerOncoMed Oncology strategic alliances and the Tuberculosis Drug Accelerator consortium He is also a member of Bayers Alliance. Read More...
Christoph Huwe
Strategic Alliance Manager Therapeutics